WO1995005138A1 - Contact adhesive extends wear time on skin - Google Patents

Contact adhesive extends wear time on skin Download PDF

Info

Publication number
WO1995005138A1
WO1995005138A1 PCT/US1994/009249 US9409249W WO9505138A1 WO 1995005138 A1 WO1995005138 A1 WO 1995005138A1 US 9409249 W US9409249 W US 9409249W WO 9505138 A1 WO9505138 A1 WO 9505138A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesive
additive
pressure sensitive
inorganic additive
skin
Prior art date
Application number
PCT/US1994/009249
Other languages
French (fr)
Inventor
Scott E. Smith
Subbu S. Venkatraman
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Priority to AU75669/94A priority Critical patent/AU7566994A/en
Publication of WO1995005138A1 publication Critical patent/WO1995005138A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/58Adhesives

Definitions

  • This invention relates to adhesive compositions for extended wear adhesion to human skin, and particularly to adhesive compositions for affixing transdermal delivery devices to human skin.
  • An acceptable adhesive for application to human skin should have a number of properties not demanded in other applications.
  • adhesives for use on human skin should adhere immediately on contact, should be capable of maintaining good adhesion over an extended period of wear (preferably without causing excessive irritation to the skin), and should upon removal release from the surface without excessive damage to the skin and without leaving a residue.
  • Such adhesives must be capable of adhering well in the warm, moist environment prevailing on human skin.
  • Many hydrophobic polymer adhesives such as acrylic adhesives are commonly used for affixing objects such as adhesive bandages or transdermal delivery patches to the skin. Most of these polymer adhesives tend to debond in the presence of moisture.
  • the wear time on human skin of objects employing hydrophobic polymer adhesives, particularly acrylic adhesives is typically four days' time or less.
  • JP 2078614 describes using a combination of a hydrophobic pressure sensitive adhesive and a hydrophilic pressure sensitive adhesive, made up of poly (vinyl) pyrrolidone and glycerol, for adhesion of a variety of "soft" materials.
  • U.S. Patent No. 4,701,509 describes improved adhesion in the presence of moisture using a hot-meltable composition that includes a copolymer of aery late monomers and a vinyl caprolactam.
  • European patent publication EP 140941 describes improved adhesion in the presence of moisture using a composition containing a copolymer of a hydrophobic ester monomer, a hydrophilic vinyl monomer and a polar comonomer. It can be advantageous in some applications, for example for transdermal delivery systems, to provide extended wear time, up to one week's time or longer.
  • hydrophobic polymer pressure sensitive adhesive compositions in the presence of moisture can be improved by adding to a hydrophobic polymer adhesive an appropriate quantity of an inorganic additive having the capacity to absorb water to a significant percentage of its weight.
  • the resulting adhesive can provide for extended wear time on human skin, as compared with the wear time of the acrylic polymer adhesive not having the inorganic additive.
  • adhesives according to the invention have improved adherency characteristics and, additionally, display improved aesthetic or cosmetic appearance.
  • Suitable additives include, for example, hydrophilic inorganic compounds which absorb or adsorb a large percentage of their weight of water.
  • These compounds have a particle size between about 3 and 100 microns, preferably between about 4 and 10 microns and include, for example, silica gel, calcium silicate, and magnesium silicate.
  • the inorganic hydrophilic additives are combined with the polymer adhesive according to the invention in proportions between about 2 % and about 20 % by weight of polymer.
  • the dynamic viscosity (measured at lower frequency) of the mixture of the hydrophobic polymer adhesive and the inorganic additive according to the invention preferably is less than, or is not substantially (no more than about 60 %) greater than, that of the adhesive alone; and more preferably the dynamic viscosity of the mixture of the hydrophobic polymer adhesive and the inorganic additive is less than 50 % (more preferably less than 40 %) greater than that of the adhesive alone.
  • the dynamic viscosity of the mixture of adhesive and additive is not substantially (preferably less than about 3 fold) decreased by exposure of the adhesive/additive mixture to moisture (100 % humidity for 24 hours).
  • the preferred formulation may vary according to the particular inorganic hydrophilic additive used.
  • silica gel was combined with an acrylate adhesive ("Morstik 607") in a proportion by weight of 10 % silica gel and 90 % Morstik; the resulting product showed greater than 80 % of initial adhesion and retained an acceptable aesthetic appearance over a 7 day period.
  • Mctik 607 an acrylate adhesive
  • the invention features a pressure sensitive adhesive composition containing a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200 % of inorganic additive weight.
  • hydrophobic is intended a material that will not absorb water by more than 5 % .
  • the inorganic hydrophilic additive and die polymer are present in the composition in a proportion between 2 % and 20 % by weight of additive to polymer.
  • Addition of the inorganic hydrophilic additive according to the invention does not substantially change the cohesive strength of the adhesive and, particularly, it does not result in a substantial increase in the cohesive strength of the adhesive.
  • Preferred hydrophobic polymers are pressure sensitive adhesives at ambient temperatures, and include polyisobutylene (PIB) or mixtures of PIB with polybutenes, and poly aery lates.
  • Preferred inorganic additives include, for example, silica gel, calcium silicate and magnesium silicate.
  • the invention features an adhesive transdermal delivery device having an adhesive layer that includes a pressure sensitive adhesive composition containing a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200% of organic additive weight.
  • Fig. 1 is a sketch, not to scale, showing an exemplary transdermal delivery device of the invention in transverse sectional view.
  • Fig. 2 is a graph showing the effect of various hydrophilic inorganic additives on the dynamic viscosity of a hydrophobic polymer adhesive.
  • Fig. 3 is a graph showing the effect of moisture on the dynamic viscosity of the Morstik adhesive, and the adhesive with an additive.
  • Figs. 4.1 - 4.3 are graphs showing wear performance characteristics of various transdermal delivery patches in an informal extended wear trial using adhesive compositions according to the invention.
  • Fig. 4.1 shows adhesion
  • Fig. 4.2 shows the extent of border formation
  • Fig. 4.3 shows the extent of irritation or erythema.
  • the adhesive compositions according to the invention are made by mixing a selected inorganic hydrophilic additive with a selected hydrophobic adhesive in appropriate proportions. Preferably, mixing is facilitated by dispersing the inorganic hydrophilic additive in an appropriate cosolvent, then admixing the hydrophobic adhesive with the cosolvent- dispersed inorganic hydrophilic additive and agitating for a time sufficient to dissolve or disperse the adhesive and the additive to apparent homogeneity.
  • the adhesive composition can men be cast and dried to form a film; for use in a transdermal delivery device, the adhesive composition according to the invention can be applied to form an adhesive lamina according to standard techniques. Typically the contact surface of the adhesive lamina is covered with a release liner for protection.
  • FIG. 1 An exemplary transdermal delivery device according to the invention is shown by way of illustration generally at 10 in Fig. 1.
  • Device 10 includes adhesive layer 14 having an upper surface covered by backing layer 12 and a basal surface covered by strippable release liner 16.
  • Adhesive layer 14 contains, according to the invention, an inorganic hydrophilic additive and a hydrophobic polymer adhesive.
  • the adhesive layer 14 constitutes a delivery matrix, which contains the substance to be transdermally delivered, together with one or more suitable vehicles and/or penetration enhancers.
  • one or more additional layers may overly adhesive layer 14, and may play any of various roles in the delivery system of the device.
  • one or more matrix layers may overly adhesive layer 14, and in such a configuration the adhesive layer need not itself serve as a delivery matrix.
  • adhesive layer 14 serves as a delivery matrix, its basal surface contacts the skin surface, and so any substance that is to be delivered from the device into and through the skin passes through adhesive layer 14.
  • the substance release rate may be modulated by the inorganic hydrophilic additive in the adhesive layer.
  • Example I Dynamic Viscosity of Adhesive With Additives
  • Adhesive Formulations 0.001 0.01 0.10 100
  • viscosity or modulus
  • viscosity or modulus values are quoted at 0.1 rad/sec or 0.01 rad/sec as being a critical parameter.
  • Adhesive polymers that are within "holding strength" (or cohesive strength) specifications vary substantially from lot to lot in viscosity.
  • the dynamic viscosity of Morstik 607 varies by as much as 50 % to 60 % at frequencies of 0.01 rad/sec or 0.1 rad/sec. Adhesives from these variable lots perform adequately for their purpose as a pressure sensitive skin contact material.
  • an inorganic additive according to the invention may be permitted to vary the viscosity of the base polymer without unacceptably changing the cohesive strength of the adhesive, is difficult to quantify.
  • increase of the viscosity by as much as about 60 % (for example, for Morstik 607) by addition of the additive can be expected not to substantially degrade pressure sensitive adhesive properties.
  • Fig. 2 shows the dynamic viscosity spectra for samples of Morstik
  • the viscosities of the samples with silica gel added to the adhesive are either lower than for the adhesive alone, or are substantially the same as for the adhesive alone (within about 20 % for the Aldrich silica gel, or within about 40 % for the Grace 74 FP, for example). Such differences are well within the range of acceptable variation in viscosity of such polymer adhesives as supplied without additives.
  • an adhesive film according to the invention was constructed using as a hydrophobic polymer Morstik 607 and using the Aldrich silica gel as an inorganic additive, and the dynamic viscosities as a function of sampling frequency were compared for the film when dry and when moistened.
  • the Morstik 607 adhesive was combined in the solvent with the Aldrich silica gel additive to 10 % w/w silica gel:Morstik 607.
  • the resulting mixture (adhesive + additive + solvent) was cast on a release liner and dried.
  • the wet layer thickness was calculated to yield a dry film of about 0.5 mm thickness.
  • a disc of diameter about .4 in (about 1 cm) was cut from the pressed dry film, and sandwiched between the parallel plates of a RMS-800. The sample was melted and the dynamic viscosity was measured as a function of frequency according to standard procedures.
  • the dynamic viscosity was measured both in dry discs cut from the adhesive mixture and in discs that had been exposed to 100% humidity for about 24 hours.
  • the resulting dynamic viscosity spectra are shown in Fig. 3. As can be seen, exposure to moisture does not change the viscosity by more than a factor of 3.
  • Adhesive compositions were made by admixing hydrophilic additives selected from those tested in Example I with a variety of acrylic adhesives, as follows. First, the selected additive was dissolved or dispersed in a cosolvent to facilitate mixing, and then die selected acrylic adhesive was added and mixed to homogeneity.
  • hydrophobic polymer adhesives may be used according to the invention, including polyacrylates, polyisobutylene (PIB) or mixtures of PIB with polybutenes.
  • the polyacrylates are copolymers of the following monomers: methyl acrylate, 2-ethylhexyl acrylate, vinyl acetate, acrylic acid, butyl acrylate and hydroxy-ethyl acrylate.
  • block copolymers of styrene/isoprene/styrene, styrene/butadiene/styrene and styrene/ethylene-butylene/styrene with suitable other resins and tackifiers are preferred hydrophobic polymers.
  • Acrylic polymers are commercially available. They include, for example, various acrylate polymers distributed by Morton Thiokol, Inc. under die tradename Morstik, or distributed by National Starch and Chemical Company under me tradename DuroTak, or distributed by Monsanto Chemical Company under me tradename Gelva. Morstik 607 (Morton Thiokol, Inc.), Gelva 737 (Monsanto Chemical Company), or DuroTak 280-1516 (National Starch and Chemical Company). - 10 -
  • acrylate polymers are suitable according to the invention for admixture with a hydrophilic additive such as calcium silicate.
  • a suitable cosolvent may be selected form the list of solvents for the adhesive.
  • the additive must be freely dispersible in the solvent.
  • Isopropyl alcohol or ethanol or ethyl acetate, for example, can be suitable according to the invention for facilitating admixture of calcium silicate in proportions up to 20 % by weight with Morstik.
  • Adhesive devices employing adhesive formulations according to the invention were constructed and tested in a human extended wear study as follows. Morstik 607 was combined witii two different silica gels (Grace Chemical 63FP and Aldrich Chemical Silica Gel), 10% by weight. The components were mixed to apparent homogeneity, then spread on a backing layer to a thickness of about 10 mils and dried to a thickness of about 5 mils. The same procedure was repeated for Morstik 607 without the additive. The resulting backed adhesive film was die-cut to form patches having an area of about 5 cm . In addition, a 30 c ⁇ r patch was also made with me Aldrich Silica Gel.
  • Fig. 4.1 shows, the patches containing silica gel maintained adhesion well above an acceptable 80% adhesion standard over the 7-day period of die study. Adhesion of die "placebo" patch containing just Morstik 607, however, showed a drop below 80% by day 3.
  • Fig. 4.2 shows the extent of "border" formation, or excess adhesive flow around die patch edge, which is also an aesthetic criterion. Since 4 mm is the acceptable aesthetic limit, the patches containing silica gel were well within the acceptable range.
  • Figure 4.3 shows the irritation or erythema levels of the patches containing silica gel. Since 2 is the acceptable limit, all the patches were acceptable with regard to erydiema as well.
  • Adhesive transdermal delivery devices can be conventionally constructed, using the adhesive formulation of the invention.
  • the adhesive layer acts as a delivery matrix, and such devices can be constructed for example by combining a substance (or substances) to be delivered with the combined acrylic polymer and inorganic hydrophilic additive prior to spreading and drying the adhesive film. It may be advantageous, depending upon me nature of the substance or substances to be delivered, additionally to combine one or more vehicles and/or enhancers with the adhesive matrix formulation. Any substance that can be administered transdermally can be delivered using an adhesive transdermal device according to me invention.
  • anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics, antihelminthics, antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers, beta-blockers such as pindolol, anti-arrythmics, antihypertensives, diuretics, and vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including antihistamine decongestants; hormones such as the estrogens estradiol and progester
  • the invention is useful for continuous or pulsed or variable rate delivery over extended periods of time, up to and exceeding one week.
  • Substances that may be advantageously administered in an extended time regime include, for example, steroid drugs, including progestogens such as norethindrone, noretiiindrone acetate, desogestrel, 3- keto desogestrel, gestadene and levonorgestrel; estrogens such as estradiol and its esters, e.g., estradiol valerate, cyprionate, deconate and acetate, as well as ethinyl estradiol; androgens such as testosterone and its esters; and corticosteroids such as cortisone, hydrocortisone, and fluocinolone acetonide.
  • me device contains and delivers a combination of one or more estrogens, particularly estradiol, and may additionally contain and deliver one or more progestogens.

Abstract

A pressure sensitive adhesive composition includes a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200 % of inorganic additive weight. The pressure sensitive adhesive is particularly useful for adhesion to human skin for extended times, and is therefore particularly suitable for use in extended-wear adhesive transdermal delivery devices. Also, an adhesive transdermal delivery device (10) has an adhesive layer (14) including such an adhesive composition.

Description

- 1 -
CONTACT ADHESIVE EXTENDS WEAR TIME ON SKIN
Background
Technical Field
This invention relates to adhesive compositions for extended wear adhesion to human skin, and particularly to adhesive compositions for affixing transdermal delivery devices to human skin.
Background Art
An acceptable adhesive for application to human skin should have a number of properties not demanded in other applications. Particularly, adhesives for use on human skin should adhere immediately on contact, should be capable of maintaining good adhesion over an extended period of wear (preferably without causing excessive irritation to the skin), and should upon removal release from the surface without excessive damage to the skin and without leaving a residue. Such adhesives must be capable of adhering well in the warm, moist environment prevailing on human skin. Many hydrophobic polymer adhesives such as acrylic adhesives are commonly used for affixing objects such as adhesive bandages or transdermal delivery patches to the skin. Most of these polymer adhesives tend to debond in the presence of moisture. As a result, the wear time on human skin of objects employing hydrophobic polymer adhesives, particularly acrylic adhesives, is typically four days' time or less.
A number of examples may be cited of acrylic polymer adhesive formulations proposed for improved adhesion in the presence of moisture.
Japanese patent publication no. JP 2078614 describes using a combination of a hydrophobic pressure sensitive adhesive and a hydrophilic pressure sensitive adhesive, made up of poly (vinyl) pyrrolidone and glycerol, for adhesion of a variety of "soft" materials. ,
U.S. Patent No. 4,701,509 describes improved adhesion in the presence of moisture using a hot-meltable composition that includes a copolymer of aery late monomers and a vinyl caprolactam.
European patent publication EP 140941 describes improved adhesion in the presence of moisture using a composition containing a copolymer of a hydrophobic ester monomer, a hydrophilic vinyl monomer and a polar comonomer. It can be advantageous in some applications, for example for transdermal delivery systems, to provide extended wear time, up to one week's time or longer.
Summary of the Invention We have discovered that the adhesion of hydrophobic polymer pressure sensitive adhesive compositions in the presence of moisture can be improved by adding to a hydrophobic polymer adhesive an appropriate quantity of an inorganic additive having the capacity to absorb water to a significant percentage of its weight. The resulting adhesive can provide for extended wear time on human skin, as compared with the wear time of the acrylic polymer adhesive not having the inorganic additive. Over extended wear times, adhesives according to the invention have improved adherency characteristics and, additionally, display improved aesthetic or cosmetic appearance. Suitable additives include, for example, hydrophilic inorganic compounds which absorb or adsorb a large percentage of their weight of water. These compounds have a particle size between about 3 and 100 microns, preferably between about 4 and 10 microns and include, for example, silica gel, calcium silicate, and magnesium silicate. The inorganic hydrophilic additives are combined with the polymer adhesive according to the invention in proportions between about 2 % and about 20 % by weight of polymer. The dynamic viscosity (measured at lower frequency) of the mixture of the hydrophobic polymer adhesive and the inorganic additive according to the invention preferably is less than, or is not substantially (no more than about 60 %) greater than, that of the adhesive alone; and more preferably the dynamic viscosity of the mixture of the hydrophobic polymer adhesive and the inorganic additive is less than 50 % (more preferably less than 40 %) greater than that of the adhesive alone. Preferably the dynamic viscosity of the mixture of adhesive and additive is not substantially (preferably less than about 3 fold) decreased by exposure of the adhesive/additive mixture to moisture (100 % humidity for 24 hours). The preferred formulation may vary according to the particular inorganic hydrophilic additive used. In one example, silica gel was combined with an acrylate adhesive ("Morstik 607") in a proportion by weight of 10 % silica gel and 90 % Morstik; the resulting product showed greater than 80 % of initial adhesion and retained an acceptable aesthetic appearance over a 7 day period.
Disclosure of the Invention Accordingly, in one general aspect, the invention features a pressure sensitive adhesive composition containing a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200 % of inorganic additive weight. By hydrophobic is intended a material that will not absorb water by more than 5 % . Preferably the inorganic hydrophilic additive and die polymer are present in the composition in a proportion between 2 % and 20 % by weight of additive to polymer. Addition of the inorganic hydrophilic additive according to the invention does not substantially change the cohesive strength of the adhesive and, particularly, it does not result in a substantial increase in the cohesive strength of the adhesive. Preferred hydrophobic polymers are pressure sensitive adhesives at ambient temperatures, and include polyisobutylene (PIB) or mixtures of PIB with polybutenes, and poly aery lates.
Preferred inorganic additives include, for example, silica gel, calcium silicate and magnesium silicate.
In another general aspect the invention features an adhesive transdermal delivery device having an adhesive layer that includes a pressure sensitive adhesive composition containing a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200% of organic additive weight.
Description of Preferred Embodiments
Preferred embodiments of the invention will now be described, beginning with a brief description of the drawings.
Brief Description of the Drawings
Fig. 1 is a sketch, not to scale, showing an exemplary transdermal delivery device of the invention in transverse sectional view.
Fig. 2 is a graph showing the effect of various hydrophilic inorganic additives on the dynamic viscosity of a hydrophobic polymer adhesive.
Fig. 3 is a graph showing the effect of moisture on the dynamic viscosity of the Morstik adhesive, and the adhesive with an additive.
Figs. 4.1 - 4.3 are graphs showing wear performance characteristics of various transdermal delivery patches in an informal extended wear trial using adhesive compositions according to the invention. Fig. 4.1 shows adhesion; Fig. 4.2 shows the extent of border formation; and Fig. 4.3 shows the extent of irritation or erythema. Modes of Carrying Out the Invention
Generally, the adhesive compositions according to the invention are made by mixing a selected inorganic hydrophilic additive with a selected hydrophobic adhesive in appropriate proportions. Preferably, mixing is facilitated by dispersing the inorganic hydrophilic additive in an appropriate cosolvent, then admixing the hydrophobic adhesive with the cosolvent- dispersed inorganic hydrophilic additive and agitating for a time sufficient to dissolve or disperse the adhesive and the additive to apparent homogeneity. The adhesive composition can men be cast and dried to form a film; for use in a transdermal delivery device, the adhesive composition according to the invention can be applied to form an adhesive lamina according to standard techniques. Typically the contact surface of the adhesive lamina is covered with a release liner for protection. An exemplary transdermal delivery device according to the invention is shown by way of illustration generally at 10 in Fig. 1. Device 10 includes adhesive layer 14 having an upper surface covered by backing layer 12 and a basal surface covered by strippable release liner 16. Adhesive layer 14 contains, according to the invention, an inorganic hydrophilic additive and a hydrophobic polymer adhesive. In a configuration such as is shown in Fig. 1, the adhesive layer 14 constitutes a delivery matrix, which contains the substance to be transdermally delivered, together with one or more suitable vehicles and/or penetration enhancers. As will be appreciated, one or more additional layers (not shown in the Fig.) may overly adhesive layer 14, and may play any of various roles in the delivery system of the device. For example, one or more matrix layers may overly adhesive layer 14, and in such a configuration the adhesive layer need not itself serve as a delivery matrix.
Whether or not adhesive layer 14 serves as a delivery matrix, its basal surface contacts the skin surface, and so any substance that is to be delivered from the device into and through the skin passes through adhesive layer 14. Depending upon whether a substance to be delivered by the device is itself more or less hydrophilic, the substance release rate may be modulated by the inorganic hydrophilic additive in the adhesive layer. The following examples illustrate the invention.
Example I Dynamic Viscosity of Adhesive With Additives The dynamic viscosities as a function of sampling frequency for an acrylic adhesive (Morstik 607, Montsanto Chemical) with four different silica gel additives (two, designated FP-74 and FP-63, from Grace
Chemicals; one from Aldrich) were measured as follows. The adhesive was combined in me solvent with the silica gel additive to 10 % w/w silica gel: Morstik 607. The resulting mixture (adhesive + additive + solvent) was cast on a release liner and the solvent was evaporated, and the resulting dry film was pressed to approximately 2 to 3 mm thickness. A disc of diameter about 1 inch (about 2.54 cm) was cut from the pressed dry film, and sandwiched between the parallel plates of a Rheometrics Mechanical Spectrometer, Version 800 ("RMS-800"). The sample was melted and the dynamic viscosity was measured as a function of frequency according to standard procedures. The resulting data are plotted as viscosity versus frequency, producing a "dynamic viscosity spectrum".
The measured viscosity of the four tested compositions at four different frequencies is shown in Table I.
Table I Viscosity of Acrylic Adhesive with and without silica gel Additives
Sampling Frequency, rad/sec
Adhesive Formulations 0.001 0.01 0.10 100
Morstik 607 4 x 107 8.5 x 106 1.8 x 106 2 x 104
Morstik 607 + 5 x 107 1.2 x lO7 1.8 x 106 2.5 x 104 10 % Grace 74 FP
Morstik 607 + 1.8 x lO7 7 x l06 1.8 x lO6 2.5 x 104 10 % Grace 63 FP
Morstik 607 + 4 x 107 1 x lO7 2.8 x 106 3 x 104 10 % Aldrich
With respect to the dynamic mechanical properties of pressure sensitive adhesives, the viscosity (or modulus) at lower frequencies is generally understood in the adhesives art to be of greatest significance in the wetting or adhesion process. See, e.g., L.-H. Lee, Ed. (1991), Adhesive Bonding, Plenum Press; particularly, e.g., Chapter 5, pp. 133-36. Thus, typically, viscosity or modulus values are quoted at 0.1 rad/sec or 0.01 rad/sec as being a critical parameter. Adhesive polymers that are within "holding strength" (or cohesive strength) specifications vary substantially from lot to lot in viscosity. The dynamic viscosity of Morstik 607, as supplied by the vendor, varies by as much as 50 % to 60 % at frequencies of 0.01 rad/sec or 0.1 rad/sec. Adhesives from these variable lots perform adequately for their purpose as a pressure sensitive skin contact material. Thus, while the acceptable range within which addition of an inorganic additive according to the invention may be permitted to vary the viscosity of the base polymer without unacceptably changing the cohesive strength of the adhesive, is difficult to quantify. Generally, increase of the viscosity by as much as about 60 % (for example, for Morstik 607) by addition of the additive can be expected not to substantially degrade pressure sensitive adhesive properties. Fig. 2 shows the dynamic viscosity spectra for samples of Morstik
607 alone (filled circles) and for Morstik 607 combined with 10 % of the silica gel additives, indicated as follows: Grace 74 FP, open circles; Aldrich, triangles; Grace 63 FP, X. Using a frequency of 0.01 rad/sec as a reference, the viscosities of the samples with silica gel added to the adhesive are either lower than for the adhesive alone, or are substantially the same as for the adhesive alone (within about 20 % for the Aldrich silica gel, or within about 40 % for the Grace 74 FP, for example). Such differences are well within the range of acceptable variation in viscosity of such polymer adhesives as supplied without additives.
Adhesive patches constructed using an adhesive according to the invention, containing Morstik 607 with silica gel additives, show extended wear over 7 days, as shown for example in Fig. 4.1.
Example II
Effect of Moisture on Dynamic Viscosity of Adhesive With Additives For this example, an adhesive film according to the invention was constructed using as a hydrophobic polymer Morstik 607 and using the Aldrich silica gel as an inorganic additive, and the dynamic viscosities as a function of sampling frequency were compared for the film when dry and when moistened. The Morstik 607 adhesive was combined in the solvent with the Aldrich silica gel additive to 10 % w/w silica gel:Morstik 607. The resulting mixture (adhesive + additive + solvent) was cast on a release liner and dried. The wet layer thickness was calculated to yield a dry film of about 0.5 mm thickness. A disc of diameter about .4 in (about 1 cm) was cut from the pressed dry film, and sandwiched between the parallel plates of a RMS-800. The sample was melted and the dynamic viscosity was measured as a function of frequency according to standard procedures.
The dynamic viscosity was measured both in dry discs cut from the adhesive mixture and in discs that had been exposed to 100% humidity for about 24 hours. The resulting dynamic viscosity spectra are shown in Fig. 3. As can be seen, exposure to moisture does not change the viscosity by more than a factor of 3.
Example III
Adhesive Compositions
Adhesive compositions were made by admixing hydrophilic additives selected from those tested in Example I with a variety of acrylic adhesives, as follows. First, the selected additive was dissolved or dispersed in a cosolvent to facilitate mixing, and then die selected acrylic adhesive was added and mixed to homogeneity.
Any of a variety of hydrophobic polymer adhesives may be used according to the invention, including polyacrylates, polyisobutylene (PIB) or mixtures of PIB with polybutenes. The polyacrylates are copolymers of the following monomers: methyl acrylate, 2-ethylhexyl acrylate, vinyl acetate, acrylic acid, butyl acrylate and hydroxy-ethyl acrylate. Further, block copolymers of styrene/isoprene/styrene, styrene/butadiene/styrene and styrene/ethylene-butylene/styrene with suitable other resins and tackifiers are preferred hydrophobic polymers. Many acrylic polymers are commercially available. They include, for example, various acrylate polymers distributed by Morton Thiokol, Inc. under die tradename Morstik, or distributed by National Starch and Chemical Company under me tradename DuroTak, or distributed by Monsanto Chemical Company under me tradename Gelva. Morstik 607 (Morton Thiokol, Inc.), Gelva 737 (Monsanto Chemical Company), or DuroTak 280-1516 (National Starch and Chemical Company). - 10 -
These acrylate polymers are suitable according to the invention for admixture with a hydrophilic additive such as calcium silicate.
A suitable cosolvent may be selected form the list of solvents for the adhesive. The additive must be freely dispersible in the solvent. Isopropyl alcohol or ethanol or ethyl acetate, for example, can be suitable according to the invention for facilitating admixture of calcium silicate in proportions up to 20 % by weight with Morstik.
Example IV Placebo Transdermal Devices
Adhesive devices employing adhesive formulations according to the invention (but not containing a substance to be delivered: "placebo patches") were constructed and tested in a human extended wear study as follows. Morstik 607 was combined witii two different silica gels (Grace Chemical 63FP and Aldrich Chemical Silica Gel), 10% by weight. The components were mixed to apparent homogeneity, then spread on a backing layer to a thickness of about 10 mils and dried to a thickness of about 5 mils. The same procedure was repeated for Morstik 607 without the additive. The resulting backed adhesive film was die-cut to form patches having an area of about 5 cm . In addition, a 30 cπr patch was also made with me Aldrich Silica Gel. One such patch was applied on day 0 to tide dry normal skin of each upper arm of 9 human volunteers. The patches and underlying skin were observed and photographed on each of days 3, 4, 5, 6 and 7. The results are shown in Figs. 4.1 through 4.3, showing adhesion characteristics, and skin condition of me subjects.
As Fig. 4.1 shows, the patches containing silica gel maintained adhesion well above an acceptable 80% adhesion standard over the 7-day period of die study. Adhesion of die "placebo" patch containing just Morstik 607, however, showed a drop below 80% by day 3. Fig. 4.2 shows the extent of "border" formation, or excess adhesive flow around die patch edge, which is also an aesthetic criterion. Since 4 mm is the acceptable aesthetic limit, the patches containing silica gel were well within the acceptable range. Figure 4.3 shows the irritation or erythema levels of the patches containing silica gel. Since 2 is the acceptable limit, all the patches were acceptable with regard to erydiema as well.
Example V Adhesive Transdermal Delivery Devices Adhesive transdermal delivery devices according to the invention can be conventionally constructed, using the adhesive formulation of the invention. In some device configurations, the adhesive layer acts as a delivery matrix, and such devices can be constructed for example by combining a substance (or substances) to be delivered with the combined acrylic polymer and inorganic hydrophilic additive prior to spreading and drying the adhesive film. It may be advantageous, depending upon me nature of the substance or substances to be delivered, additionally to combine one or more vehicles and/or enhancers with the adhesive matrix formulation. Any substance that can be administered transdermally can be delivered using an adhesive transdermal device according to me invention. These include anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics, antihelminthics, antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers, beta-blockers such as pindolol, anti-arrythmics, antihypertensives, diuretics, and vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including antihistamine decongestants; hormones such as the estrogens estradiol and progesterone and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedative; and tranquilizers.
Particularly, the invention is useful for continuous or pulsed or variable rate delivery over extended periods of time, up to and exceeding one week. Substances that may be advantageously administered in an extended time regime include, for example, steroid drugs, including progestogens such as norethindrone, noretiiindrone acetate, desogestrel, 3- keto desogestrel, gestadene and levonorgestrel; estrogens such as estradiol and its esters, e.g., estradiol valerate, cyprionate, deconate and acetate, as well as ethinyl estradiol; androgens such as testosterone and its esters; and corticosteroids such as cortisone, hydrocortisone, and fluocinolone acetonide. For some therapies, me device contains and delivers a combination of one or more estrogens, particularly estradiol, and may additionally contain and deliver one or more progestogens.
Other Embodiments
Other embodiments are within the following claims.

Claims

Claims
1. A pressure sensitive adhesive composition comprising a hydrophobic polymer and an inorganic additive that is capable of absorbing water up to 200 % of inorganic additive weight, me dynamic viscosity of said composition containing said inorganic additive being substantially the same as or less than the dynamic viscosity of such a composition not containing said inorganic additive.
2. The pressure sensitive adhesive composition of claim 1, wherein said inorganic additive is present in a proportion in the range about 2 % to about 20 % by weight of said hydrophobic polymer.
3. The pressure sensitive adhesive composition of claim 1, wherein said inorganic additive is present in a proportion in the range about 5 % to about 10 % by weight of said acrylic polymer.
4. The pressure sensitive adhesive composition of claim 1, wherein said inorganic additive is one of silica gel, calcium silicate and magnesium silicate.
5. The pressure sensitive adhesive composition of claim 1, wherein said hydrophobic polymer is an acrylic polymer.
6. An adhesive transdermal delivery device, having an adhesive layer made up of the adhesive composition of claim 1.
PCT/US1994/009249 1993-08-16 1994-08-16 Contact adhesive extends wear time on skin WO1995005138A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75669/94A AU7566994A (en) 1993-08-16 1994-08-16 Contact adhesive extends wear time on skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10732393A 1993-08-16 1993-08-16
US08/107,323 1993-08-16

Publications (1)

Publication Number Publication Date
WO1995005138A1 true WO1995005138A1 (en) 1995-02-23

Family

ID=22316042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009249 WO1995005138A1 (en) 1993-08-16 1994-08-16 Contact adhesive extends wear time on skin

Country Status (2)

Country Link
AU (1) AU7566994A (en)
WO (1) WO1995005138A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829713C1 (en) * 1998-07-03 2000-01-05 Lohmann Therapie Syst Lts Therapeutic system with the addition of pearlescent pigments
WO2010088697A3 (en) * 2009-02-02 2011-01-27 Medtronic, Inc. Antimicrobial accessory for an implantable medical device
US8758807B2 (en) 2006-12-20 2014-06-24 Coloplast A/S Pressure sensitive adhesive composition comprising salt
US8858983B2 (en) 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
US9186335B2 (en) 2002-07-30 2015-11-17 Ucb Pharma Gmbh Hot melt TTS for administering rotigotine
US9642850B2 (en) 1997-02-24 2017-05-09 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
US10251844B2 (en) 1998-03-30 2019-04-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system and method of use thereof for treating parkinsonism

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015107743A1 (en) * 2015-05-18 2016-11-24 Bsn Medical Gmbh Silicone gel coated adhesive layer structure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918128A (en) * 1987-12-25 1990-04-17 Toppan Moore Co., Ltd. Pressure-sensitive adhesive
US5260064A (en) * 1990-04-06 1993-11-09 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneous-administration-type pharmaceutical preparation of nitroglycerin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918128A (en) * 1987-12-25 1990-04-17 Toppan Moore Co., Ltd. Pressure-sensitive adhesive
US5260064A (en) * 1990-04-06 1993-11-09 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneous-administration-type pharmaceutical preparation of nitroglycerin

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642850B2 (en) 1997-02-24 2017-05-09 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
US10251844B2 (en) 1998-03-30 2019-04-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system and method of use thereof for treating parkinsonism
US10322093B2 (en) 1998-03-30 2019-06-18 Ucb Biopharma Sprl Method for producing a transdermal therapeutic system which contains a D2 agonist
DE19829713C1 (en) * 1998-07-03 2000-01-05 Lohmann Therapie Syst Lts Therapeutic system with the addition of pearlescent pigments
US9186335B2 (en) 2002-07-30 2015-11-17 Ucb Pharma Gmbh Hot melt TTS for administering rotigotine
US8758807B2 (en) 2006-12-20 2014-06-24 Coloplast A/S Pressure sensitive adhesive composition comprising salt
EP2853245A1 (en) 2006-12-20 2015-04-01 Coloplast A/S A pressure sensitive adhesive composition comprising salt
WO2010088697A3 (en) * 2009-02-02 2011-01-27 Medtronic, Inc. Antimicrobial accessory for an implantable medical device
US8858983B2 (en) 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system

Also Published As

Publication number Publication date
AU7566994A (en) 1995-03-14

Similar Documents

Publication Publication Date Title
US5980932A (en) Solid matrix system for transdermal drug delivery
CA2065311C (en) Solid matrix system for transdermal drug delivery
AU671020B2 (en) Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
CA1092466A (en) Topical device for administering tretinoin
EP1061900B1 (en) Dermal compositions
KR100425556B1 (en) Drug Release Controlled Percutaneous Absorbent
US5059189A (en) Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5820878A (en) Percutaneously absorbable patch
US20060078601A1 (en) Compositions and methods for delivering estradiol in transdermal drug delivery systems
AU2004238119B2 (en) External patch containing estrogen and/or progestogen
ZA200603300B (en) Transdermal drug delivery device
HU219465B (en) Styrol-isoprene-styrol-based transdermal matrix system containing oestrogen or progestogen component or mixture thereof as active ingredient, and process for producing it
JPH08143451A (en) Percutaneous absorption preparation
JP2587365B2 (en) Preparation of transdermal preparations
WO1995005138A1 (en) Contact adhesive extends wear time on skin
CN103784425A (en) Percutaneous administration device of bisoprolol
WO1996040087A2 (en) Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
JP4008532B2 (en) Transdermal absorption patch preparation
JP2688778B2 (en) Patch for disease treatment
JP2503095B2 (en) Patch
JPS60123416A (en) Drug delivery member
JPS597687B2 (en) medical parts
JPH0336806B2 (en)
JP3407895B2 (en) Method for evaluating skin irritation of patches and patches
JPH02295565A (en) Sticking material

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA